FFAR4 and polycystic ovary syndrome: One week after administration, compared with the PCOS-IR group, both the PCOS-IR+GPR120 agonist group and the PCOS-IR+LrB (40 mg/kg) group showed significant reductions in body weight (Figure 2B).